r, as more cases are solved, the benefits quickly add up. “We’re talking about small subsets of patients that together make a radi- cal change,” says Funda Meric-Bernstam, chair of the Department of Investigational Cancer Therapeutics at MD Anderson, who leads the unusual responders pro- gram. In some cases, existing c